Phio Pharmaceuticals Corp. - 10-Q Filing
Phio Pharmaceuticals reported a net loss of $4.0 million for the first quarter ended March 31, 2026, compared to a net loss of $1.8 million in Q1 2025. The company's operating expenses increased significantly from $1.9 million to $4.2 million year-over-year due to higher research and development costs ($2.8 million vs. $0.9 million) and general administrative expenses ($1.4 million vs. $1.0 million). Cash and cash equivalents decreased by $4.0 million during the quarter, ending at $17.0 million as of March 31, 2026.
Tickers: $PHIO